Literature DB >> 31580067

Cyanine-Assisted Exfoliation of Covalent Organic Frameworks in Nanocomposites for Highly Efficient Chemo-Photothermal Tumor Therapy.

Kui Wang1,2,3, Zhe Zhang1,3, Lin Lin1,2,3, Kai Hao1,2,3, Jie Chen1,2,3, Huayu Tian1,2,3, Xuesi Chen1,2,3.   

Abstract

Covalent organic frameworks (COFs) have received considerable interest because of their advanced applications. However, their low dispersibility and aqueous stability are intractable issues limiting their biomedical application. To address the issue, water-dispersible nanocomposites (COF@IR783) produced through the assembly of cyanines and COFs are proposed and prepared. Therefore, a strategy of "killing three birds with one stone" is developed. First, the nanocomposites exhibit superior dispersibility and aqueous stability compared to COFs. The nanocomposites have a nanosized morphology and negative charges, which are in favor of improving the blood circulation and enhanced permeability and retention-mediated tumor-targeting delivery therapy for in vivo application. Second, the nanocomposites have enhanced photothermal therapy (PTT) ability in the near-infrared region compared to cyanines. The nanocomposites also have a photoacoustic imaging ability, which can guide the antitumor therapy in vivo. Lastly, the nanocomposites can be further used as drug-delivery carriers for loading the anticancer cis-aconityl-doxorubicin (CAD) prodrug. In comparison with individual PTT or chemotherapy, the combination of PTT and chemotherapy achieved with COF@IR783@CAD synergistically induced the death of cancer cells in vitro, and an intravenous injection of COF@IR783@CAD in mice resulted in significant tumor ablation. This work indicates that the dispersibility and aqueous stability of COFs can be appropriately overcome through a rational design and can further expand the biomedical applications of COFs.

Entities:  

Keywords:  aqueous exfoliation; chemotherapy; covalent organic frameworks; cyanines; enhanced photothermal therapy

Mesh:

Substances:

Year:  2019        PMID: 31580067     DOI: 10.1021/acsami.9b13544

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  7 in total

1.  Emerging 2D Nanomaterials for Biomedical Applications.

Authors:  Aparna Murali; Giriraj Lokhande; Kaivalya A Deo; Anna Brokesh; Akhilesh K Gaharwar
Journal:  Mater Today (Kidlington)       Date:  2021-06-17       Impact factor: 31.041

Review 2.  Nanoscale covalent organic frameworks as theranostic platforms for oncotherapy: synthesis, functionalization, and applications.

Authors:  Qun Guan; Guang-Bo Wang; Le-Le Zhou; Wen-Yan Li; Yu-Bin Dong
Journal:  Nanoscale Adv       Date:  2020-07-16

Review 3.  Heptamethine Cyanine-Based Application for Cancer Theranostics.

Authors:  Lei Zhang; Hang Jia; Xuqian Liu; Yaxin Zou; Jiayi Sun; Mengyu Liu; Shuangshuang Jia; Nan Liu; Yanzhang Li; Qun Wang
Journal:  Front Pharmacol       Date:  2022-02-11       Impact factor: 5.810

Review 4.  Progress and Viewpoints of Multifunctional Composite Nanomaterials for Glioblastoma Theranostics.

Authors:  Ming-Hsien Chan; Wen-Tse Huang; Aishwarya Satpathy; Ting-Yi Su; Michael Hsiao; Ru-Shi Liu
Journal:  Pharmaceutics       Date:  2022-02-21       Impact factor: 6.321

5.  Templated Assembly of pH-Labile Covalent Organic Framework Hierarchical Particles for Intracellular Drug Delivery.

Authors:  Fangzhou Zhou; Yuanyuan Fang; Chao Deng; Qian Zhang; Minying Wu; Hsin-Hui Shen; Yi Tang; Yajun Wang
Journal:  Nanomaterials (Basel)       Date:  2022-09-02       Impact factor: 5.719

6.  Photoresponsive prodrug-dye nanoassembly for in-situ monitorable cancer therapy.

Authors:  Kaiqi Long; Yifan Wang; Wen Lv; Yang Yang; Shuting Xu; Changyou Zhan; Weiping Wang
Journal:  Bioeng Transl Med       Date:  2022-03-12

Review 7.  Covalent organic framework nanomedicines: Biocompatibility for advanced nanocarriers and cancer theranostics applications.

Authors:  Nem Singh; Jungryun Kim; Jaewon Kim; Kyungwoo Lee; Zehra Zunbul; Injun Lee; Eunji Kim; Sung-Gil Chi; Jong Seung Kim
Journal:  Bioact Mater       Date:  2022-09-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.